Features

 
 
  • Vascular Surgeons, Interventionalists Clash Over Guidelines The Society of Vascular Surgery's decision to publish guidelines on extracranial carotid disease after signing on to a multisociety guidance on carotid disease is not sitting well with other societies.
  • Indian echo project takes remote diagnosis to new level A unique "medical mission" using handheld echo in a remote rural population in India is being hailed as a success after cardiologists around the globe logged on over a two-day period to read the echocardiograms of unseen patients half a world away.
  • Wine and chocolate: Flavonoid and polyphenol research continues The field of flavonoids and polyphenols continues to attract a massive amount of interest, from researchers and the public alike. But can health really be improved by eating chocolate and drinking red wine?
  • Biggest cardiology news of 2011 What made headlines in 2011? Everything from novel oral anticoagulants, blockbuster trials stopped early, and a new scrutiny on procedure appropriateness. heartwire reporters called up cardiologists across 11 different subspecialties to ask them what they thought the biggest news was in their field this past year.
  • Cardiologists support elective PCI without on-site CABG Is elective angioplasty without surgical backup on-site safe and effective enough for the US? Where would you send a family member? Sparks flew on both sides of the debate, as captured in a survey conducted jointly by theheart.org and US News & World Report.
  • Physicians must become politically active to aid tobacco-control efforts Global leaders in the fight against smoking stress that cardiologists and other physicians must become politically active to help counteract the immense power of the tobacco industry, which is constantly seeking to expand the number of smokers worldwide. Doctors have a voice, and they need to step out of their comfort zone and use it to effect change, say activists.
  • Glory: Is cancer beating cardiovascular disease? Part 3 Asked what disease they fear most, people overwhelmingly list cancer over heart disease. In the last of a three-part series, heartwire looks at how much public support, fundraising, and volunteerism the two diseases have garnered in recent years and whether cancer's long stint in the limelight may be what's boosting research opportunities and new therapies as CVD lags behind.
  • Money: Is cancer beating cardiovascular disease? Part 2 Heart disease is the number-one killer in most of the Western world, followed closely by cancer. But a close look at just how much money is available to support research in both fields points to some striking disparities.
  • Drugs: Is cancer beating CVD? Part 1 Heart disease is the number-one killer in most of the Western world, followed closely by cancer. But a close look at recent drug approvals and pipeline projects speaks to an explosion of new treatments for killer number two, while heart-disease treatments fall behind.
  • Cardiac rehab: What works, what doesn't, and why Attendance at a cardiac rehabilitation program after a cardiac event reduces the risk of death and future events, but uptake is notoriously low. Prohibitive costs, poor communication, and a laissez-faire attitude on the part of physicians are all a part of the problem.
  • What Future for Niacin After AIM-HIGH? It is now a month after the surprise announcement by NHLBI that it was stopping the AIM-HIGH trial of extended-release niacin for patients with low HDL and high triglycerides because of futility.
  • The looming epidemic of adult congenital heart disease Where once they died young, these days most of the 1% of children worldwide born with congenital heart defects now survive to adulthood and need to be followed long term. The majority, however, fall off the radar when they become young adults, in part due to a lack of doctors skilled in adult congenital heart disease.
  • ACC If CV Prevention Gets a Boost, Does It Matter Who Pays? The ACC says solid disclosure and protection policies are in place, but some are asking whether money donated by a fast-food restaurant and soda company, among others, lead to more harm than good.
  • Mehra, Starling, and Greenberg on Cheney's transplant prospects The former vice president was recently implanted with a left ventricular assist device, but was it for bridge therapy, destination therapy, or "bridge to decision"? How suitable would he be for transplantation? Three expert observers discuss his case with heartwire.
  • Quinidine Fades; Pharma Asked to Put Patients Before Profits The situation has gotten so bad that one physician recently couriered a few boxes of quinidine to a colleague halfway around the world who couldn't access it in his own country.
  • Pocket-sized echo devices Impressively capable for imaging and undeniable cool as technology, the current generation of smart-phone-sized ultrasound devices may be a leap forward for some uses, but experts warn they aren't a substitute for fully featured echo systems.
  • Cardiac imaging radiation The growth of cardiac imaging is fueling concern over radiation exposure, especially for newer imaging modalities such as CT angiography and for so-called "episodes of care." Some experts are raising radiation alarms for other, older tests, while others point out that pinning down the true cancer risks from any type of test is more guesswork than science.
  • New oral anticoagulants: How do they compare? It seems likely that there will be two new oral anticoagulants available in the not-too-distant future that can be used as an alternative to warfarin in the prevention of stroke in AF patients. But how do the two new agents compare with each other, and what about other possible indications and the host of other similar agents in development?
  • ICD remote monitoring for following advisory devices Implantable defibrillator checks conducted remotely, usually over phone lines or cellular networks, are an especially efficient way to keep tabs on device performance and any arrhythmic events. They also help cut down on office visits and may offer a particular advantage for patients with Sprint Fidelis leads or any others subject to a "recall" or safety advisory. So why isn't remote monitoring
  • Bioabsorbable stents: The future Bioabsorbable stents have been hailed as a solution to problems that dog metallic stents, but not everybody is sure what role the vanishing scaffolds will one day play in clinical practice. Some experts see a more expansive role for the devices, such as implanting the bioabsorbable stents into vulnerable arteries that wouldn't today meet criteria for stenting. Others, however, envision using the